Even when approved I think Nuvaring sales will be small.
The main game is dermatology, Metric Contract Services and Nextstellis.
Also Mithra is in late stage trials for a version of Nexstellis that helps women deal with menopause. That is a huge market and hopefully Mayne Pharma can partner with Mithra in the US and Australia given the relationship and 10% shareholding in MYX.
Cheers.....D
MYX Price at posting:
29.3¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)